Debating role of vancomycin for MRSA at #IDWeek2022.
Dr Wagner argues that increasing duration of MRSA bacteraemia associated with poorer outcomes (mortality).
I accept this.
BUT, therapeutically reducing duration of bacteraemia has not been associated with improved mortality.
Dr Wagner argues that increasing duration of MRSA bacteraemia associated with poorer outcomes (mortality).
I accept this.
BUT, therapeutically reducing duration of bacteraemia has not been associated with improved mortality.
Duration of bacteremia is a SURROGATE. Although logical and biologically plausible that reducing duration of bacteremia with a particular antibiotic (vs another) should improve the outcome we care about (mortality), this has not yet been demonstrated.
Cites 43% of patients with trough-based dosing develop AKI.
We didn't find this in CAMERA2. Almost all on vanc and trough-based dosing. In control arm only 6% developed AKI. jamanetwork.com/journals/jama/…
Yes, that was in the context of a clinical trial. But 6% is far from 43%
We didn't find this in CAMERA2. Almost all on vanc and trough-based dosing. In control arm only 6% developed AKI. jamanetwork.com/journals/jama/…
Yes, that was in the context of a clinical trial. But 6% is far from 43%
• • •
Missing some Tweet in this thread? You can try to
force a refresh
